This review highlights tirzepatide, a novel dual agonist of GLP-1 and GIP receptors, which has demonstrated significant improvements in glycemic control, weight loss, and potential cardiovascular and renal benefits, marking it as a promising advancement in T2D treatment
Patients with high baseline triglycerides ( 150 mg/dL) levels showed a relatively greater reduction in apoC-III compared with those presenting normal levels
However, this is a minor factor compared to temperature, light, and solvent choice
Association between lifetime cigarette smoking and Lewy body accumulation
This is directly relevant for anyone on GLP 1 medications
Drinking adequate fluids and monitoring for persistent symptoms can help